NEW AMBRX BIOPHARMA INC (AMAM)
US6418711080 - Common Stock
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders...
3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount.
3 Stocks to Buy That Are Up 200% or More in 2024
Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
INVESTIGATION ALERT: Halper Sadeh LLC Investigates AXNX, AMAM, FGH
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RYZB, FGH, AXNX, AMAM
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FGH, AMAM, AXNX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
First Week of March 15th Options Trading For New Ambrx Biopharma (AMAM)
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)
On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
Ambrx Holders Who Bought for Pennies See 6,700% Gain on J&J Bid
Longtime believers in Ambrx Biopharma Inc. are being rewarded with juicy returns as Johnson & Johnson’s buyout offer values the biotech stock at more than 6,700% of its all-time low.
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news.
Johnson & Johnson to acquire Ambrx Biopharma (NYSE:JNJ)
Johnson & Johnson (JNJ) to acquire Ambrx Biopharma (AMAM) for around $2B in a deal to boost its drug pipeline with antibody-drug conjugates. (ADCs). Read more here.